PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31357056-5	2019	In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25).	Ribavirin	128-137	solute carrier family 17 member 5	Homo sapiens	77-103	
31357056-5	2019	In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25).	Ribavirin	128-137	solute carrier family 17 member 5	Homo sapiens	105-108	
31357056-5	2019	In this trial, LF associated mortality is reduced for patients with elevated aspartate aminotransferase (AST) when treated with ribavirin (OR 0.41, 95% CI 0.23-0.73), while mortality is higher for patients without elevated AST (OR 2.37, 95% CI 1.07-5.25).	Ribavirin	128-137	solute carrier family 17 member 5	Homo sapiens	223-226	
12723514-4	2003	Ribavirin monotherapy was associated with a significant decrease in AST, ALT and gamma glutamyl transpeptidase levels.	Ribavirin	0-9	solute carrier family 17 member 5	Homo sapiens	68-71	
1916970-3	1991	Mean levels of ALT and AST were significantly lower in the ribavirin treated group as compared to the placebo group on days 5, 10 and 14; serum bilirubin levels were significantly lower in the ribavirin group on days 10 and 14.	Ribavirin	59-68	solute carrier family 17 member 5	Homo sapiens	23-26	
35211422-6	2022	A generalized additive mixed model (GAMM) was conducted to analyze the trending shift of aspartate aminotransferase/alanine transaminase-ratio (AST/ALT-ratio) and platelet (PLT) in SFTS patients treated with ribavirin.	Ribavirin	208-217	solute carrier family 17 member 5	Homo sapiens	144-147	
35211422-16	2022	Treatment with ribavirin could increase PLT count while decreasing AST/ALT-ratio within SFTS patients.	Ribavirin	15-24	solute carrier family 17 member 5	Homo sapiens	67-70	
7534082-4	1995	Ribavirin-induced haemolysis was clinically significant in three patients, necessitating a reduction in the daily dose of ribavirin from 1.2 g to 0.2 g. Comparison of the pre- and post-treatment biopsy specimens in the four patients who tolerated the full dose of ribavirin and who had normal AST levels at the end of 6 months of treatment showed significant histological improvement with reduction in either lobular or periportal inflammation in all of the patients and a reduction in periportal fibrosis in one patient.	Ribavirin	0-9	solute carrier family 17 member 5	Homo sapiens	293-296	
32568409-4	2020	During early treatment with peg-IFN-a2a plus ribavirin, the imbalance of these Tc17/IFN-gamma cells could be partially restored, together with normalized serum ALT but not AST.	Ribavirin	45-54	solute carrier family 17 member 5	Homo sapiens	172-175